Back To: Home : Featured Technology : High Throughput Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Cytochrome P450 inhibition assays for drug-drug interaction
June 2007
SHARING OPTIONS:

BioTrove, Inc. announced the release of a fully validated suite of twelve cytochrome P450 inhibition assays for performing drug-drug interaction (DDI) assays on the RapidFire Mass Spectrometry platform (RF-MS). With throughputs approaching fluorescence- or radioactivity-based methods (3500 data points per eight-hour shift on a single instrument), and full compatibility with liver microsome preparations, the RapidFire P450 inhibition assay platform enables researchers to advance lead optimization with highly accurate mass spectrometric data. With a capacity of up to 18 standard 96- or 384-well microtiter plates of P450 inhibition assays, the RapidFire system works with any commercially available triple-quadrupole mass spectrometer for walk-away analysis.  Following a fully integrated and automated on-line sample purification and mass spectrometric data acquisition, custom RapidFire Integrator software facilitates the analysis of thousands of samples in a single step, outputting the data in a flexible format ready for import into databases. Because the RapidFire system does not require a dedicated mass spectrometer and consumes a minimal amount of solvent per sample analyzed, operational costs are greatly reduced.
 
BioTrove Inc.
781-721-3600

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.